BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3365919)

  • 1. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
    Steiner E; Dumont E; Spina E; Dahlqvist R
    Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
    Spina E; Steiner E; Dumont E; Dahlqvist R
    Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
    [No Abstract]   [Full Text] [Related]  

  • 3. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators.
    Steiner E; Spina E
    Clin Pharmacol Ther; 1987 Sep; 42(3):278-82. PubMed ID: 3621781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
    Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
    Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine.
    Spina E; Arena A; Pisani F
    Ther Drug Monit; 1987 Jun; 9(2):129-33. PubMed ID: 3617150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active metabolites of imipramine and desipramine in man.
    Potter WZ; Calil HM; Sutfin TA; Zavadil AP; Jusko WJ; Rapoport J; Goodwin FK
    Clin Pharmacol Ther; 1982 Mar; 31(3):393-401. PubMed ID: 7060321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
    J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Duan SX; Harmatz JS; Shader RI
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1278-83. PubMed ID: 8138941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
    Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
    Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.
    von Bahr C; Spina E; Birgersson C; Ericsson O; Göransson M; Henthorn T; Sjöqvist F
    Biochem Pharmacol; 1985 Jul; 34(14):2501-5. PubMed ID: 4015690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenobarbital induces the 2-hydroxylation of desipramine.
    Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
    Ther Drug Monit; 1996 Feb; 18(1):60-4. PubMed ID: 8848823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desipramine hydroxylation: variability and effect of antipsychotic drugs.
    Bock JL; Nelson JC; Gray S; Jatlow PI
    Clin Pharmacol Ther; 1983 Mar; 33(3):322-8. PubMed ID: 6130865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.
    Cooke RG; Warsh JJ; Stancer HC; Reed KL; Persad E
    Clin Pharmacol Ther; 1984 Sep; 36(3):343-9. PubMed ID: 6467794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine.
    Hedman A; Angelin B; Arvidsson A; Dahlqvist R; Nilsson B
    Clin Pharmacol Ther; 1990 Jan; 47(1):20-6. PubMed ID: 2295215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.
    Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of carbamazepine on the 2-hydroxylation of desipramine.
    Spina E; Avenoso A; Campo GM; Caputi AP; Perucca E
    Psychopharmacology (Berl); 1995 Feb; 117(4):413-6. PubMed ID: 7604141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slow hydroxylation of tricyclic antidepressants--relationship to polymorphic drug oxidation.
    Sjöqvist F; Bertilsson L
    Prog Clin Biol Res; 1986; 214():169-88. PubMed ID: 3523507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.